Leo Pharma poised to market new drug every 2-3 years
Dermatology company Leo Pharma turns its eyes towards 2030 with a new strategy to help cement the group’s position on the skin disease treatment market and to firmly position the company in the US.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
Leo Pharma hits the speeder as the company now plans to shower the market with new treatments for both rare and more common skin diseases.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
